970 related articles for article (PubMed ID: 29937226)
1. LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade.
Sheng W; LaFleur MW; Nguyen TH; Chen S; Chakravarthy A; Conway JR; Li Y; Chen H; Yang H; Hsu PH; Van Allen EM; Freeman GJ; De Carvalho DD; He HH; Sharpe AH; Shi Y
Cell; 2018 Jul; 174(3):549-563.e19. PubMed ID: 29937226
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous Inhibition of LSD1 and TGFβ Enables Eradication of Poorly Immunogenic Tumors with Anti-PD-1 Treatment.
Sheng W; Liu Y; Chakraborty D; Debo B; Shi Y
Cancer Discov; 2021 Aug; 11(8):1970-1981. PubMed ID: 33687985
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
4. PD-1 Expression during Acute Infection Is Repressed through an LSD1-Blimp-1 Axis.
Bally APR; Neeld DK; Lu P; Majumder P; Tang Y; Barwick BG; Wang Q; Boss JM
J Immunol; 2020 Jan; 204(2):449-458. PubMed ID: 31811020
[TBL] [Abstract][Full Text] [Related]
5. WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway.
Guo E; Xiao R; Wu Y; Lu F; Liu C; Yang B; Li X; Fu Y; Wang Z; Li Y; Huang Y; Li F; Wu X; You L; Qin T; Lu Y; Huang X; Ma D; Mills GB; Sun C; Chen G
J Exp Med; 2022 Jan; 219(1):. PubMed ID: 34825915
[TBL] [Abstract][Full Text] [Related]
6. Targeting Nuclear LSD1 to Reprogram Cancer Cells and Reinvigorate Exhausted T Cells via a Novel LSD1-EOMES Switch.
Tu WJ; McCuaig RD; Tan AHY; Hardy K; Seddiki N; Ali S; Dahlstrom JE; Bean EG; Dunn J; Forwood J; Tsimbalyuk S; Smith K; Yip D; Malik L; Prasanna T; Milburn P; Rao S
Front Immunol; 2020; 11():1228. PubMed ID: 32612611
[TBL] [Abstract][Full Text] [Related]
7. Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC.
Nguyen EM; Taniguchi H; Chan JM; Zhan YA; Chen X; Qiu J; de Stanchina E; Allaj V; Shah NS; Uddin F; Manoj P; Liu M; Cai SF; Levine R; Quintanal-Villalonga Á; Sen T; Chow A; Rudin CM
J Thorac Oncol; 2022 Aug; 17(8):1014-1031. PubMed ID: 35691495
[TBL] [Abstract][Full Text] [Related]
8. LSD1 silencing contributes to enhanced efficacy of anti-CD47/PD-L1 immunotherapy in cervical cancer.
Xu S; Wang X; Yang Y; Li Y; Wu S
Cell Death Dis; 2021 Mar; 12(4):282. PubMed ID: 33731702
[TBL] [Abstract][Full Text] [Related]
9. LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer.
Shen DD; Pang JR; Bi YP; Zhao LF; Li YR; Zhao LJ; Gao Y; Wang B; Wang N; Wei L; Guo H; Liu HM; Zheng YC
Mol Cancer; 2022 Mar; 21(1):75. PubMed ID: 35296335
[TBL] [Abstract][Full Text] [Related]
10. LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade.
Liu Y; Debo B; Li M; Shi Z; Sheng W; Shi Y
Nat Commun; 2021 Nov; 12(1):6831. PubMed ID: 34819502
[TBL] [Abstract][Full Text] [Related]
11. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
12. E3 ligase Trim35 inhibits LSD1 demethylase activity through K63-linked ubiquitination and enhances anti-tumor immunity in NSCLC.
Tang F; Lu C; He X; Lin W; Xie B; Gao X; Peng Y; Yang D; Sun L; Weng L
Cell Rep; 2023 Dec; 42(12):113477. PubMed ID: 37979167
[TBL] [Abstract][Full Text] [Related]
13. Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential.
Bao L; Zhu P; Mou Y; Song Y; Qin Y
Front Immunol; 2023; 14():1214675. PubMed ID: 37483603
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing.
Hiatt JB; Sandborg H; Garrison SM; Arnold HU; Liao SY; Norton JP; Friesen TJ; Wu F; Sutherland KD; Rienhoff HY; Martins R; Houghton AM; Srivastava S; MacPherson D
Clin Cancer Res; 2022 Oct; 28(20):4551-4564. PubMed ID: 35920742
[TBL] [Abstract][Full Text] [Related]
15. PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade.
Srour N; Villarreal OD; Hardikar S; Yu Z; Preston S; Miller WH; Szewczyk MM; Barsyte-Lovejoy D; Xu H; Chen T; Del Rincón SV; Richard S
Cell Rep; 2022 Mar; 38(13):110582. PubMed ID: 35354055
[TBL] [Abstract][Full Text] [Related]
16. Targeting LSD1 suppresses stem cell-like properties and sensitizes head and neck squamous cell carcinoma to PD-1 blockade.
Han Y; Xu S; Ye W; Wang Y; Zhang X; Deng J; Zhang Z; Liu L; Liu S
Cell Death Dis; 2021 Oct; 12(11):993. PubMed ID: 34689153
[TBL] [Abstract][Full Text] [Related]
17. Lysine-Specific Demethylase 1 (LSD1)-Mediated Epigenetic Modification of Immunogenicity and Immunomodulatory Effects in Breast Cancers.
Lee DY; Salahuddin T; Iqbal J
Curr Oncol; 2023 Feb; 30(2):2127-2143. PubMed ID: 36826125
[TBL] [Abstract][Full Text] [Related]
18. LSD1 Inhibition Enhances the Immunogenicity of Mesenchymal Stromal Cells by Eliciting a dsRNA Stress Response.
Mardani F; Saad W; El-Hachem N; Bikorimana JP; Kurdi M; Shammaa R; Talbot S; Rafei M
Cells; 2022 Jun; 11(11):. PubMed ID: 35681511
[TBL] [Abstract][Full Text] [Related]
19. LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation.
He Y; Zhao Y; Wang L; Bohrer LR; Pan Y; Wang L; Huang H
Oncogene; 2018 Jan; 37(4):534-543. PubMed ID: 28991226
[TBL] [Abstract][Full Text] [Related]
20. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
